Sunitinib - A new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 6, 2007, Pages 342-343

  Debiec Rychter, Maria ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY; SKIN DISCOLORATION; UNSPECIFIED SIDE EFFECT;

EID: 34249889909     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0814     Document Type: Short Survey

References (4)

1. Heinrich MC et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349
2. Debiec-Rychter M et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103
3. Heinrich MC et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774
4. Prenen H et al. (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627